October 05, 2007
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Lawrence V. Gulotta, MD
Answorth A. Allen, MD
David W. Altchek, MD
Kenneth Chambers, MD
Struan H. Coleman, MD, PhD
Frank A. Cordasco, MD, MS
Edward V. Craig, MD, MPH
Brian de Palma
Demetrios Delos, MD
David M. Dines, MD
Joshua Dines, MD
Kevin DiSilvestro
Stephen Fealy, MD
Mark Figgie, MD
Steven R. Goldring, MD
Jo A. Hannafin, MD, PhD
Kristofer Jones, MD
Richard Kang, MD
Heather Kawalick
EmilyYing Lai
Yuo-yu (Lily) Lee
Stephen Lyman, PhD
John D. MacGillivray, MD
Gregory Mahony
Lisa Mandl, MD, MPH
Andrew Merritt, MD
Danyal Nawabi, MD
Stephen O’Brien, MD, MBA
Delia Pais
Scott A. Rodeo, MD
Howard Anthony Rose, MD
Beth Shubin Stein, MD
Russell F. Warren, MD
Thomas L. Wickiewicz, MD
Riley J. Williams III, MD
We will enroll all TSA patients who undergo surgery at HSS and consent to be in the study. We estimate this to be approximately 200 patients a year. Patients will receive follow-up questionnaires at one year, two years and five years after their surgery.
Patients 18 years or older undergoing total shoulder arthroplasty at HSS
Principal Investigator
Lawrence Gulotta, MD
646.797.8735
Research Coordinator
Gregory Mahony
212.774.2449